In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 151 for your search:
Drug:  trastuzumab
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: H4621g, NCT00833963

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML25477, NCT01260194

3.

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487

4.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: PUMCH- Breast-AH, NCT01413828

5.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR005143, EPOANE3010, 2005-001817-17, NCT00338286

6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 74
Sponsor: Other
Protocol IDs: HERNATA, NCT00430001

7.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: M06HER, 2006-001707-11, NCT00459771

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Protocol number FBCSG-01-2007, EudraCT number 2007-002016-26, NCT00593697

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: TOP, NCT00637325

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: WMS-PERSEPHONE, MREC-PERSEPHONE, PERSEPHONE, EUDRACT: 2006-007018-39, ISRCTN 52968807, MREC 07/MRE08/35, PERSEPHONE, EU-20858, CRUK-BRD/07/137, NCT00712140

11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00702, CDR0000615085, NSABP-B-43, U10CA012027, NCT00769379

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001J2301, 2008-006556-21, NCT00876395

13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 112515, NCT00968968

14.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000669882, ICR-CTSU-2008-10017, UM-EPHOS-B, CRUK-08-002, MREC-09-H1208-52, ISRCTN-15004993, EUDRACT-2008-005466-30, EU-21029, GSK-ICR-CTSU-2008-10017, UM-CR-CTSU/2008/10017,EPHOS-B, NCT01104571

15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 70 to 80
Sponsor: Other
Protocol IDs: N-SAS BC 07, RESPECT, NCT01104935

16.

Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 114299, NCT01160211

17.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02601, CDR0000683717, RTOG 1010, U10CA021661, NCT01196390

18.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02572, NSABP-B-47, CDR0000692574, U10CA012027, NCT01275677

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO27798, 2011-001526-19, NCT01450696

20.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICORG 11-10, NCT01526369

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28048, 2011-005328-17, NCT01566721

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO28047, 2011-005334-20, NCT01572038

23.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BCD-022-02, NCT01764022

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO27938, 2012-002018-37, NCT01772472

25.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO25114, NCT01774786
1     
New Search